With bacteriuria detection in 15 minutes and antibiotic effectiveness determined within 30, Sysmex’s PA-100 AST System is changing the landscape of UTI care. Backed by economic projections in Spain and awarded the prestigious £8 million Longitude Prize, the system offers a powerful weapon against antimicrobial resistance.
The PA-100 AST System from Sysmex is setting a new gold standard in diagnosing and managing urinary tract infections. Leveraging state-of-the-art nanofluidic technology and rapid antimicrobial susceptibility testing (AST), the system delivers reliable results in under 45 minutes — a marked improvement over traditional lab methods that often take days.
UTIs: A widespread issue requiring urgent innovation
Affecting more than 400 million individuals each year, urinary tract infections are among the most common bacterial infections worldwide. However, delays in testing and the frequent use of empirical antibiotics often lead to poor outcomes and rising antimicrobial resistance (AMR). Sysmex’s PA-100 AST System addresses these issues directly with its high sensitivity (84%) and specificity (99%), empowering clinicians to make accurate, timely decisions.
Alain Baverel, President & CEO Sysmex Europe SE, remarked,
“The PA-100 AST System represents a pivotal innovation in the fight against antimicrobial resistance. By providing clinicians with rapid and precise diagnostic insights, we can transform how urinary tract infections are treated globally. This tool not only benefits patients but also strengthens the financial sustainability of healthcare systems.”
Economic modelling in Spain indicates major financial gains
In a recently published analysis, the integration of the PA-100 AST System into Spain’s public health infrastructure could result in annual savings of €323 million, assuming full adoption. These savings come from reduced hospitalisations, fewer secondary complications, and a decrease in productivity losses. Over a three-year span, further cumulative cost reductions are projected.
Takashi Ono, Member of the Managing Board and Senior Executive Officer & Managing Director of Sysmex Corporation, commented, “By addressing one of the leading causes of antibiotic misuse, Sysmex’s PA-100 AST System aligns perfectly with global efforts to combat antimicrobial resistance. The system empowers healthcare providers with the data needed to make the right decision at the right time, benefiting patients and public health alike.”
PA-100 AST System was awarded the Longitude Prize
Beyond its economic and clinical utility, the system’s achievements have been widely recognised. Last year, the PA-100 AST System was awarded the Longitude Prize, an £8 million award dedicated to innovations addressing AMR. This accolade underscores the system’s capacity to enhance patient outcomes and mitigate the global AMR crisis.
Identifies bacteriuria within 15 minutes
The PA-100 AST System’s innovative approach utilises a compact, smartphone-sized cartridge to identify bacteriuria in 15 minutes & determine effective antibiotics in the subsequent 30 minutes. This reduces treatment delays and complications.
Know more about the PA-100 AST System
